References

N
Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016.
Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-583.
Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Lawitz EJ, Pockros PJ, Gitlin N, et al., eds. Hepatology. 2015;61(4):1127-1135.
Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41(5):830-836.
Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540. doi:10.2807/1560-7917.ES.2017.22.21.30540.
Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61(5):pii: e02558-16. doi:10.1128/AAC.02558-16. Print 2017 May.
Ng T, Lu L, Reisch T, et al. Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes. Krishnan P, Schnell G, Tripathi R, et al., eds. J Hepatol. 2017;66(1):S324.
Nguyen J, Barritt AS, Jhaveri R. Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C infection. J Pediatr. 2019;(207):90-96. doi:10.1016/j.jpeds.2018.12.012.
Nguyen E, Trinh S, Trinh H, et al. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther. 2019;49(1):99-106. doi:10.1111/apt.15043.
Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry L. Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naïve or experienced patients. Am J Gastroenterol. 2017;112(12):1824-1831. doi:10.1038/ajg.2017.399.
Nielsen J, Christensen VB, Borgwardt L, Rasmussen A, Ostrup O, Kjaer MS. Prognostic molecular markers in pediatric liver disease - Are there any?. Biochim Biophys Acta Mol Basis Dis. 2019;(1865):577-586.
Noda K, Yoshihara H, Suzuki K, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res. 1996;20(1 Suppl):95A-100A.
Nolan S, DiasLima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109(12):2053-2059.
Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Steinman M, DeLuca J, Cunningham CO, Johnson N, Laraque F, Litwin AH, eds. Int J Drug Policy. 2017;47:196-201.
Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. Am J Med. 2000;109(1):62-64.
O
O'Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis. 2014;1(3):ofu110.
O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100-105.
O'Leary JG, Fontana RJ, Brown K, et al. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Burton, Jr JR, Firpi-Morell R, Muir A, et al., eds. Transpl Int. 2017;30(2):196 - 208.
Kosloski MP, Dutta S, Ding B, et al. Interactions between ABT-493 plus ABT-530 combination and rilpivirine or raltegravir [poster #453]. Oberoi RK, Hu B, Wang S, Kort J, Liu W, eds. Conference on Retroviruses and Opportunistic Infections. 2016.
Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002;97(9):2408-2414.
Top